Amneal Pharmaceuticals, Inc. has made a modest $50m raise to its full-year guidance following a successful second quarter, which saw the firm continue to shift its generics business toward complex products while its bevacizumab biosimilar exceeded expectations. The firm now expects a net revenue of $2.3bn to $2.4bn for 2023.
It has also raised its 2023 adjusted EBITDA guidance range to $525m-$540m, up about $20m from the prior range of...